Gene therapy for melanoma

Dermatologic Therapy

Volumn 10, Issue , 1999, Pages 74-82

  Esche, Clemens ^b   Shurin, Michael R ^b   Lotze, Michael T ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; COLONY STIMULATING FACTOR 1; DACARBAZINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; CELL STIMULATION; DENDRITIC CELL; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOGENICITY; MELANOMA; MOUSE; NONHUMAN; REVIEW; SKIN CANCER; SUICIDE GENE; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

EID: 0033004436     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Esche C, Lokshin A, Lotze MT, Shurin MR. Murine and human melanoma induces apoptosis of dendritic cells: a potential mechanism of tumor-induced immunosuppression. J Invest Dermatol 1998: 110: 630a.
2. Esche C, Lokshin A, Gastman BR, Lotze MT, Shurin MR. Melanoma-induced apoptosis of dendritic cells is regulated by Bcl-2 and Bax. Exp Dermatol 1998: 7: 414a.
3. Esche C, Gambotto A, Robbins P, Watkins SC, Lotze MT, Shurin MR. CD154 (CD40L) expression inhibits tumor growth in an IL-12-dependent fashion and promotes dendritic cell survival. J Immunother 1998: 21: 464a.
4. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaes RM, Anderson W. Gene transfer into humans: Immunotherapy of patients with advanced melanoma using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990: 323: 570-578.
5. Anderson WF. Human gene therapy. Nature 1998: 392: 25-30.
6. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 1998: 80: 35-47.
7. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons AV, Karasuyama H, Vogelstein B, Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990: 60: 397-403.
8. Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschle M, Maass G, Payer E, Stingl G, Birnstiel ML. Elicitation of a systemic and protective anti-melanoma immune response by an IL-12-based vaccine. Assessment of critical cellular and molecular parameters. J Immunol 1995: 154: 3406-3419.
9. Arienti F, Sule-Suso J, Belli F, Mascheroni L, Rivoltini L, Melani C, Maio M, Cascinelli N, Colombo MP, Parmiani G. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 1996: 7: 1955-1963.
10. Kim TS, Russell SJ, Collins MKL, Cohen EP. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma. Int J Cancer 1993: 55: 865-872.
11. Kim TS, Xu WS, Sun T, Cohen EP. Immunization with interleukin-2/interferon-γ double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma. Melanoma Res 1995: 5: 217-227.
12. Hollingsworth SJ, Darling D, Gaken J, Hirst W, Patel P, Kuiper M, Towner P, Humphreys S, Farzaneh F, Mufti GJ. The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma. Br J Cancer 1996: 74: 6-15.
13. Shurin MR, Esche C, Peron JM, Lotze MT. Anti-tumor activities of Interleukin-12 and mechanisms of action. Chem Immunol 1997: 68: 153-174.
14. Tahara H, Zeh H Jr, Storkus WJ, Pappo J, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994: 54: 182-189.
15. Nanni P, Ross I, De Giovanni C, Landuzzi L, Nicoletti G, Stoppaciaro A, Parenza M, Colombo MP, Lollini PL. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res 1998: 58: 1225-1230.
16. Sun Y, Jurgovsky K, Moller P, Alijagic S, Georgieva J, Wittig B, Schadendorf D. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 1998: 5: 481-490.
17. Abdel-Wahab Z, Weltz C, Hester D, Pickett N, Vervaert C, Barber JR, Jolly D, Seigler HF. A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer 1997: 80: 401-412.
18. Shurin MR, Esche C, Lokshin A, Lotze MT. Apoptosis in dendritic cells. In: Lotze MT, Thomson AW, ed. Dendritic cells. Biology and clinical application. San Diego: Academic Press, 1999: 673-692.
19. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989: 57: 503-512.
20. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992: 257: 548-551.
21. Missol E, Sochanik A, Szala S. Introduction of murine IL-4 gene into B16(F10) melanoma tumors by direct gene transfer with DNA-liposome complexes. Cancer Lett 1995: 97: 189-193.
22. Suminami Y, Elder EM, Lotze MT, Whiteside TL. In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother 1995: 17: 238-248.
23. Sun WH, Kreisle RA, Phillips AW, Ershler WB. In vivo and in vitro characteristics of interleukin-6-transfected B16 melanoma cells. Cancer Res 1992: 52: 5412-5415.
24. Mackiewicz A, Gorny A, Laciak M, Malicki J, Murawa P, Nowak J, Wiznerowicz M, Hawley RG, Heinrich PC, Rose-John S. Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum Gene Ther 1995: 6: 805-811.
25. Aoki T, Tashiro K, Miyatake T, Nakano T, Oda Y, Kikuchi H, Honjo T. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci U S A 1992: 89: 3850-3854.
26. Möller P, Sun Y, Dorbic T, Alijagic S, Makki A, Jurgovsky K, Schroff M, Henz BM, Wittig B, Schadendorf D. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer 1998: 77: 1907-1916.
27. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993: 90: 3539-3543.
28. Walsh P, Dorner A, Duke RC, Su LJ, Glode LM. Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma. J Natl Cancer 1995: 87: 809-816.
29. Ogasawara M, Rosenberg SA. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes. Cancer Res 1993: 53: 3561-3568.
30. Marr RA, Hitt M, Muller WJ, Gauldie J, Graham FL. Tumour therapy in mice using adenovirus vectors expressing human TNFa. Int J Oncol 1998: 12: 509-515.
31. Shurin MR, Esche C, Lotze MT. FLT3: Receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev 1998: 9: 37-48.
32. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JCL. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 1997: 3: 625-631.
33. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol 1998: 161: 6164-6170.
34. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 1998: 58: 380-383.
35. Esche C, Subbotin VM, Hunter OC, Peron JM, Lotze MT, Shurin MR. Accumulation and maturation of murine skin dendritic cells are regulated by flt3 ligand and interleukin-12. J Leukocyte Biol 1998: suppl 2: 75a.
36. Schwarz RH. A cell culture model for T-lymphocyte clonal anergy. Science 1990: 248: 1349-1356.
37. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970: 169: 1042-1049.
38. Liu Y, Janeway CA. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T-cells. Proc Nat Acad Sci U S A 1992: 89: 3845-3849.
39. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lamier LL, Somoza C. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993: 366: 76-79.
40. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman F, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989: 143: 2714-2722.
41. Freeman GJ, Gray GS, Gimmi CD, Lombard DB, Zhou LJ, White M, Fingeroth JD, Gribben JG, Nadler LM. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 1991: 174: 625-631.
42. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, Gray GS, Nadler LM. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993: 262: 909-911.
43. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992: 71: 1093-1102.
44. + T cells by B7-transfected melanoma cells. Science 1993: 259: 368-370.
45. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 1994: 153: 421-428.
46. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE. Tumor immunogenicity determines the effect of B7 Costimulation on T cell-mediated tumor immunity. J Exp Med 1994: 179: 523-532.
47. + melanoma. Int Immunol 1993: 5: 1501-1508.
48. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 1993: 90: 11307-11311.
49. Stopek AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, Warneke J, Schluter SF, Stahl S. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997: 15: 341-349.
50. Chong H, Hutchinson G, Hart IR, Vile RG. Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum Gene Ther 1996: 7: 1771-1779.
51. Dummer R, Yue FY, Pavlovic J, Geertsen R, Dohring C, Moelling K, Burg G. Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10. Br J Cancer 1998: 77: 1413-1419.
52. Esche C, Shurin MR, Lotze MT. The use of dendritic cells for cancer vaccination. Curr Opin Mol Ther 1999: 1: 72-81.
53. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998: 392: 86-89.
54. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via alphabeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998: 188: 1359-1368.
55. Knight SC, Hunt R, Dore C, Medawar PB. Influence of dendritic cells on tumor growth. Proc Natl Acad Sci U S A 1985: 82: 4495-4497.
56. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nat Med 1995: 1: 1297-1302.
57. Celluzzi C, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 1996: 183: 283-287.
58. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996: 184: 465-472.
59. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997: 70: 706-715.
60. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997: 186: 1177-1182.
61. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998: 4: 328-332.
62. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet 1997: 349: 2-3.
63. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, Amin KM, Kaiser LR, Albelda SM. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996: 3: 85-92.
64. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992: 256: 1550-1552.
65. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993: 53: 3860-3864.
66. Vile GR, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994: 54: 6228-6234.
67. Bonnekoh B, Greenhalgh DA, Bundman DS, Eckhardt JN, Longley MA, Chen SH, Woo SL, Roop DR. Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol 1995: 104: 313-317.
68. Bonnekoh B, Greenhalgh DA, Bundman DS, Kosai K, Chen SH, Finegold MJ, Krieg T, Woo SL, Roop R. Adenoviral-mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma. J Invest Dermatol 1996: 106: 1163-1168.
69. Albino AP, Vidai NS, McNutt NS, Shea CR, Prieto VG, Nanus DM, Palmer JM, Hayward NK. Mutation and expression of the p53 in human malignant melanoma. Melanoma Res 1994: 4: 35-45.
70. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991: 352: 345-347.
71. Liu TJ, El-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, Clayman GL. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous-cell carcinoma of the head and neck. Cancer Res 1995: 55: 3117-3122.
72. Cirielli C, Riccioni T, Yang C, Pili R, GIoe T, Chang J, Inyaku K, Passaniti A, Capogrossi MC. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int J Cancer 1995: 63: 673-679.
73. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998: 90: 273-286.